Prelude Therapeutics (PRLD) Non-Current Assets (2019 - 2026)
Prelude Therapeutics (PRLD) posted Non-Current Assets of $35.0 million for Q1 2026, down 1.61% sequentially from $35.6 million in Q4 2025, and down 9.8% YoY from $38.9 million in Q1 2025.
Prelude Therapeutics (PRLD) Non-Current Assets (2019 - 2026) Analysis & Trends
Prelude Therapeutics has reported Non-Current Assets for 8 years, with the latest figure at $35.0 million in Q1 2026.
- Quarterly Non-Current Assets fell 9.8% year-over-year to $35.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $145.1 million (down 9.79% YoY) and the FY2025 annual result came in at $35.6 million, down 10.09% from the prior year.
- Non-Current Assets eased to $35.0 million in Q1 2026 per PRLD's latest filing, from $35.6 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $42.1 million in Q4 2023 and troughed at $10.4 million in Q2 2022.
- A 5-year average of $30.0 million and a median of $35.6 million in 2025 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2022 and 2025: Non-Current Assets jumped 190.11% in 2022, then decreased 10.8% in 2025.
- Over 5 years, Non-Current Assets stood at $16.1 million in 2022, then jumped by 161.02% to $42.1 million in 2023, then fell by 5.84% to $39.6 million in 2024, then dropped by 10.09% to $35.6 million in 2025, then retreated by 1.61% to $35.0 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $35.0 million, $35.6 million, and $36.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Prelude Therapeutics | 442.91 Mn | 162.28 Mn | - | 34.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 34.47 Mn |
| Mar 31, 2026 | 35.05 Mn |
| Dec 31, 2025 | 35.62 Mn |
| Sep 30, 2025 | 36.43 Mn |
| Jun 30, 2025 | 38.04 Mn |
| Mar 31, 2025 | 38.86 Mn |
| Dec 31, 2024 | 39.62 Mn |
| Sep 30, 2024 | 40.83 Mn |
| Jun 30, 2024 | 41.58 Mn |
| Mar 31, 2024 | 41.74 Mn |
| Dec 31, 2023 | 42.08 Mn |
| Sep 30, 2023 | 23.60 Mn |
| Jun 30, 2023 | 20.40 Mn |
| Mar 31, 2023 | 23.06 Mn |
| Dec 31, 2022 | 16.12 Mn |
| Sep 30, 2022 | 15.43 Mn |
| Jun 30, 2022 | 10.43 Mn |
| Mar 31, 2022 | 10.70 Mn |
| Dec 31, 2021 | 9.98 Mn |
| Sep 30, 2021 | 5.32 Mn |